company background image
ONC

Oncimmune Holdings AIM:ONC Stock Report

Last Price

UK£0.45

Market Cap

UK£31.5m

7D

2.8%

1Y

-72.5%

Updated

01 Dec, 2022

Data

Company Financials
ONC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

ONC Stock Overview

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally.

Oncimmune Holdings plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oncimmune Holdings
Historical stock prices
Current Share PriceUK£0.45
52 Week HighUK£1.80
52 Week LowUK£0.42
Beta0.64
1 Month Change-16.11%
3 Month Change-47.93%
1 Year Change-72.55%
3 Year Change-1.52%
5 Year Change-61.93%
Change since IPO-65.81%

Recent News & Updates

Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Aug 16
Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Recent updates

Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Aug 16
Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Shareholder Returns

ONCGB BiotechsGB Market
7D2.8%1.1%1.0%
1Y-72.5%-33.4%-6.0%

Return vs Industry: ONC underperformed the UK Biotechs industry which returned -36.2% over the past year.

Return vs Market: ONC underperformed the UK Market which returned -6.7% over the past year.

Price Volatility

Is ONC's price volatile compared to industry and market?
ONC volatility
ONC Average Weekly Movement9.5%
Biotechs Industry Average Movement7.6%
Market Average Movement5.8%
10% most volatile stocks in GB Market11.1%
10% least volatile stocks in GB Market2.8%

Stable Share Price: ONC is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ONC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
201552Adam Hillhttps://www.oncimmune.com

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.

Oncimmune Holdings plc Fundamentals Summary

How do Oncimmune Holdings's earnings and revenue compare to its market cap?
ONC fundamental statistics
Market CapUK£31.46m
Earnings (TTM)-UK£9.51m
Revenue (TTM)UK£3.86m

8.2x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ONC income statement (TTM)
RevenueUK£3.86m
Cost of RevenueUK£2.40m
Gross ProfitUK£1.46m
Other ExpensesUK£10.97m
Earnings-UK£9.51m

Last Reported Earnings

May 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.14
Gross Margin37.76%
Net Profit Margin-246.49%
Debt/Equity Ratio-362.7%

How did ONC perform over the long term?

See historical performance and comparison